Muestra métricas de impacto externas asociadas a la publicación. Para mayor detalle:
| Indexado |
|
||||
| DOI | 10.1016/J.ARBRES.2020.07.022 | ||||
| Año | 2021 | ||||
| Tipo | artículo de investigación |
Citas Totales
Autores Afiliación Chile
Instituciones Chile
% Participación
Internacional
Autores
Afiliación Extranjera
Instituciones
Extranjeras
Introduction: While the molecular mechanisms of COPD pathogenesis remain obscure, there is mounting evidence supporting a key role for autoimmunity. Although human leukocyte antigens (HLA) alleles have been repeatedly associated with autoimmune processes, the relation between HLA and COPD remains largely unexplored, especially in Latin American (LA) populations. Consequently, this study aimed to investigate the presence of HLA class I and II alleles in COPD patients and healthy controls in a LA population with admixed ancestry. Methods: COPD patients (n = 214) and age-matched controls (n = 193) were genotyped using the Illumina Infinium Global Screening Array. The classic HLA alleles were imputed using HLA Genotype Imputation with Attribute Bagging (HIBAG) and the Hispanic reference panel. Finally, the distribution of HLA-DRB1 alleles was reexamined in 510 randomly recruited unrelated volunteers. Results: CODP patients showed a higher HLA-DRB1*01:02 allele frequency (6.54%) than healthy controls (3.27%, p = 0.04, OR = 2.07). HLA-DRB1*01:02 was also significantly associated with FEV1 (p = 0.04) and oxygen saturation (p = 0.02), and the FEV1/FVC ratio was higher in HLA-DRB1*15:01-positive patients (p = 9 × 10−3). Conclusion: We report an association among HLA-DRB1 alleles, COPD risk and pulmonary function parameters for the first time in Latin Americans. Since HLA-DRB1 genetic variability relates to the individual autoimmune response, these results support a role of autoimmunity in the pathogenesis of COPD.
| Ord. | Autor | Género | Institución - País |
|---|---|---|---|
| 1 | Diaz, Roberto | Hombre |
Universidad Autónoma de Chile - Chile
Health Research Institute of Santiago de Compostela (IDIS) - España Hlth Res Inst Santiago IDIS - España Health Research Institute of Santiago (IDIS) - España Instituto de Investigación Sanitaria de Santiago de Compostela - España |
| 2 | Silva, Rafael S. | Hombre |
Hospital Regional de Talca - Chile
|
| 3 | Hosgood, H. Dean | Hombre |
Albert Einstein College of Medicine of Yeshiva University - Estados Unidos
Albert Einstein Coll Med - Estados Unidos Albert Einstein College of Medicine - Estados Unidos |
| 3 | Hosgood, H. Dean | - |
Albert Einstein Coll Med - Estados Unidos
|
| 4 | Jaime, Sergio | Hombre |
Hospital Regional de Talca - Chile
|
| 5 | Miravitlles, M. | Hombre |
Vall d'Hebron Institut de Recerca - España
Hosp Univ Vall dHebron - España |
| 6 | Oquequi, Jordi | Hombre |
Universidad Autónoma de Chile - Chile
|
| Fuente |
|---|
| Fondo Nacional de Desarrollo Científico y Tecnológico |
| Comisión Nacional de Investigación Científica y Tecnológica |
| GlaxoSmithKline |
| Comisión Nacional de Investigación CientÃfica y Tecnológica |
| Fondo Nacional de Desarrollo CientÃfico y Tecnológico |
| AstraZeneca |
| Boehringer Ingelheim |
| Chilean National Science and Technology Fund |
| Chilean National Science and Technology Fund (CONICYT), FONDECYT |
| Chiesi Farmaceutici |
| Teva Pharmaceutical Industries |
| Verona Pharma |
| Agradecimiento |
|---|
| Funding support for this study was provided by the Chilean National Science and Technology Fund (CONICYT) , FONDECYT Project N° 11150022. |
| Marc Miravitlles has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Bial, Sandoz, Zambon, CSL Behring, Grifols and Novartis, consulting fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Bial, Gebro Pharma, CSL Behring, Laboratorios Esteve, Ferrer, Mereo Biopharma, Verona Pharma, TEVA, pH Pharma, Novartis and Grifols and research grants from GlaxoSmithKline and Grifols, all outside the submitted work. |
| Funding support for this study was provided by the Chilean National Science and Technology Fund (CONICYT), FONDECYT Project No 11150022. |